BART1 Polyclonal Antibody BT-AP00838
Specifications
| 20ul / 50ul / 100ul |
Background:
ADP-ribosylation factor (ARF)-like proteins (ARLs) comprise a functionally distinct group of the ARF family of RAS-related GTPases. The protein encoded by this gene binds to ARL2.GTP with high affinity but does not interact with ARL2.GDP, activated ARF, or RHO proteins. The lack of detectable membrane association of this protein or ARL2 upon activation of ARL2 is suggestive of actions distinct from those of the ARFs. This protein is considered to be the first ARL2-specific effector identified, due to its interaction with ARL2.GTP but lack of ARL2 GTPase-activating protein activity.
Classification:
Primary antibody
Alternative names:
ARL2BP; BART; BART1; ADP-ribosylation factor-like protein 2-binding protein; ARF-like 2-binding protein; Binder of ARF2 protein 1
Species reactivity:
Human;Mouse;Rat
Host:
Rabbit
Isotype:
IgG
Immunogen:
The antiserum was produced against synthesized peptide derived from human ARL2BP. AA range:101-150
Concentration:
1 mg/ml
Molecular weight:
18822
Applications:
WB, ELISA
Storage:
-20°C for one year
More info:
Email: info@sobekbio.com
Orders:
Email: orders@sobekbio.com
Fine Biotech is an ISO9001:2008 Certified Company,offers a full line of quality research kits,which include ELISA Kits,related ELISA assistant reagents and more high quality antibodies, recombinant proteins. Fine Biotech technical support are delicated to providing with professional and friendly assistance for our customers. Strict and multiple quality control ensure that our products continue to successfully supply for the international market. Moreover, we strive to continuously improve the customer experience through comprehensive technical support. High quality,rapid turnaround and personal support for all FineTest services are guaranteed. Should you have any problems,or any ideas on ways that we can improve our service,please feel free to call upon us.Thank you for your interest in FineTest products and we look forward to supplying you in the near future.